WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005102325) USE OF C-KIT INHIBITORS FOR TREATING INFLAMMATORY MUSCLE DISORDERS INCLUDING MYOSITIS AND MUSCULAR DYSTROPHY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/102325    International Application No.:    PCT/IB2005/001367
Publication Date: 03.11.2005 International Filing Date: 19.04.2005
IPC:
A61K 31/421 (2006.01), A61K 31/426 (2006.01), A61K 31/506 (2006.01)
Applicants: AB SCIENCE [FR/FR]; 3, avenue George V, F-75008 Paris (FR) (For All Designated States Except US).
MOUSSY, Alain [FR/FR]; (FR) (For US Only).
KINET, Jean-Pierre [FR/US]; (US) (For US Only)
Inventors: MOUSSY, Alain; (FR).
KINET, Jean-Pierre; (US)
Agent: MARTIN, Jean-Jacques; Cabinet Regimbeau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR)
Priority Data:
60/563,460 20.04.2004 US
Title (EN) USE OF C-KIT INHIBITORS FOR TREATING INFLAMMATORY MUSCLE DISORDERS INCLUDING MYOSITIS AND MUSCULAR DYSTROPHY
(FR) UTILISATION D'INHIBITEURS DE C-KIT POUR LE TRAITEMENT DE TROUBLES MUSCULAIRES INFLAMMATOIRES COMPRENANT LA MYOSITE ET LA DYSTROPHIE MUSCULAIRE
Abstract: front page image
(EN)The present invention relates to a method for treating inflammatory muscle disorders including myositis and muscular dystrophy comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cell degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
(FR)L'invention concerne un procédé permettant de traiter des troubles musculaires inflammatoires, notamment la myosite et la dystrophie musculaire, qui consiste à administrer à un humain nécessitant un tel traitement un composé pouvant affaiblir des mastocytes ou un composé inhibant la dégranulation de mastocytes. Ces composés peuvent être choisis parmi des inhibiteurs de c-kit, plus précisément, des inhibiteurs de c-kit puissants, sélectifs et non toxiques. De préférence, ledit inhibiteur est incapable de favoriser la mort de cellules dépendantes de IL-3 cultivées en présence de IL-3.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)